User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -0.67% 147.50 145.00 150.00 149.50 147.50 149.50 68,911 16:09:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 84

Reneuron Share Discussion Threads

Showing 8201 to 8223 of 8300 messages
Chat Pages: 332  331  330  329  328  327  326  325  324  323  322  321  Older
DateSubjectAuthorDiscuss
12/3/2021
08:34
#RENE as company’s progress they need different senior leaders. Reneuron are entering late stage development & so need a highly skilled deal maker who can be strong with the large institutions & big pharma’s they will talk with. Shame to see Michael Hunt go,but new CFO needed IMO https://twitter.com/Trader__007/status/1370290467229859845
zho
12/3/2021
08:12
Market seems to like it
volsung
12/3/2021
08:11
I'm amazed - after all, we are only just around the corner from the promised inflection points that will move the share price into the stratosphere... :-)
onceaday
12/3/2021
08:10
perhaps the job has outgrown him? without knowing anything about him, its evident that the job over the last year or so and definitely going forward is going to require a different set of skills in respect to the finance raising, deals, city liaison. Someone whose spent 21 years in the job is probably not going to be the right person to take the company forward, it's most likely going to need a lot more effort and a different skill set. I wish him all the best, but also look forward to the company announcing a more experienced hire.
bg23
12/3/2021
07:48
CFO leaving not usually a good thing But there is not much to CFO at a bio and he wasn't the most enthusiastic of presenters so maybe it's genuinely him looking to move on and do something new
the stigologist
12/3/2021
07:38
He is obviously not good at selling company to City or potential investors or share price would not be this low. Needs a stronger voice?
ayl30
12/3/2021
07:31
Michael Hunt resigns suddenly. What's that all about?
dickbush
09/3/2021
22:32
What's happening with Huntingtons?
supernumerary
08/3/2021
10:57
Most things I have seem to be tanking Maybe a good time to accumulate. Got some more of these at 98.6p
volsung
03/3/2021
09:35
Rene did a presentation on AJ Bell / Shares Mag webinar a couple of days ago, so this may have stimulated some buying interest. Seemed to go well I thought.
jpuff
27/2/2021
11:58
https://www.youtube.com/watch?v=xnMxH6QjED8
dickbush
26/2/2021
10:01
By its own admission, the RP product is several years away from possible marketing, even assuming success, although moving to phase 3 testing in a year's time might be enough to bring in deals/bidders. The excitement here is exosomes, the latest hot technology in this sector as evidenced by the prices paid for companies in this area. As always with RENE, investors are left in the dark as to how far they are along with proving its success in carrying other molecules to their targets and improving outcomes for patients. This is two years old https://www.youtube.com/watch?v=wa47CfniyLQ
dickbush
25/2/2021
10:04
What’s the point of presentations? What we want to know is plain and simple..does it’s science work? Everyone is looking for something that cures..not a presentation of hopes.
rayrac
18/2/2021
18:22
Bit more info on the Evox funding; hTTps://www.fiercebiotech.com/biotech/evox-therapeutics-reels-95m-to-propel-exosome-based-pipeline
pdt
18/2/2021
10:07
I see Evox has raised £70m in an oversubscribed third round financing for its exosomes. The article I read in the Telegraph also mentioned a listing in the US in the longer term which may shine a light on the true value of Rene's interest in this space. Clearly huge interest in exosomes at the moment and there should be newsflow over the next six months with new pharma collaborations and data from existing ones for Reneuron. I was really here for the value in Eye disease but I am coming around to the hidden value in this part of the company. Added to my holding today.
pdt
17/2/2021
11:46
4BB started today at c120p now 350p The market loves Cell and Gene Therapy stories right now
the stigologist
16/2/2021
15:52
Woodford's coming back. I wonder if he is still interested in RENE. They are about 25% of the price he paid, and several years further on in their development "Woodford will manage a familiar set of holdings as part of his new venture, including Immunocore, Oxford Nanopore Technologies Ltd. and Arix Bioscience Plc. Acacia purchased the portfolio for 224 million pounds from Woodford’s now-liquidated fund, and the holdings are now worth around 690 million pounds as many of them benefited from a rally in healthcare stocks during the pandemic." Read more at: https://www.bloombergquint.com/onweb/woodford-s-second-act-begins-with-assets-that-led-to-downfall
dickbush
12/2/2021
18:49
Interesting!
rayrac
12/2/2021
16:30
Good finish nice set up for next week
the stigologist
12/2/2021
09:03
Nice vol this am
ayl30
11/2/2021
20:09
Good set up .
the stigologist
11/2/2021
11:30
Lauders, many thanks for that article. RENE's management has mentioned the possibility of its exosomes being useful in fighting COVID-19, but I thought it was just a try on to boost the share price. Now, if today's announcement of increased options is, heaven forbid, related to this article in the Times of Israel, we may see those option targets realised a lot sooner than 3 years. I can dream...
dickbush
11/2/2021
10:20
cant get a live quote
latifs100
Chat Pages: 332  331  330  329  328  327  326  325  324  323  322  321  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210507 20:36:43